Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor.
John M. Ketcham,David M. Briere,Aaron C. Burns,James G. Christensen,Robin J. Gunn,Jacob Haling,Anthony Ivetac, Shilpi Khare,Jon Kuehler,Svitlana Kulyk,Jade Laguer, John D. Lawson,Krystal Moya,Natalie Nguyen,Peter Olson,Lisa Rahbaek,Christopher R. Smith,Niranjan Sudhakar,Nicole C. Thomas,Darin Vanderpool,Xiaolun Wang,Matthew A. Marx CANCER RESEARCH(2022)
AI 理解论文
溯源树
样例